Mitomycin C Injection: Product Description and Uses
Mitomycin C is an antineoplastic agent derived from the bacterium Streptomyces caespitosus. It is primarily used in the treatment of various types of cancer, including bladder cancer, gastric cancer, and pancreatic cancer. Mitomycin C works by inhibiting DNA synthesis, leading to cell death, particularly in rapidly dividing cancer cells. This medication is typically administered via injection and is often used in combination with other chemotherapy agents to enhance its efficacy.
Uses of Mitomycin C
- Bladder Cancer: Used as a treatment option for superficial bladder cancer, often administered intravesically (directly into the bladder).
- Gastric Cancer: Employed in the treatment of advanced gastric cancer, particularly in combination with other chemotherapeutic agents.
- Pancreatic Cancer: Utilized in the management of pancreatic cancer, especially in cases where surgery is not an option.
- Other Cancers: May also be used in the treatment of other malignancies, including breast cancer and lung cancer, depending on the clinical scenario.
Technical Data
| Parameter | Details |
|---|---|
| Generic Name | Mitomycin C |
| Brand Name | Mutamycin, others |
| Drug Class | Antineoplastic agent |
| Formulation | Injection (lyophilized powder) |
| Strengths Available | 5 mg, 10 mg, 20 mg |
| Route of Administration | Intravenous (IV), Intravesical |
| Mechanism of Action | Alkylating agent that cross-links DNA, inhibiting DNA synthesis and function |
| Indications | Bladder cancer, gastric cancer, pancreatic cancer, and other malignancies |
| Common Side Effects | Nausea, vomiting, myelosuppression, fatigue, and potential for pulmonary toxicity |
| Storage Conditions | Store at room temperature (20-25°C), protect from light |
| Shelf Life | Typically 24 months from the date of manufacture |
Important Considerations
- Dosage: The dosage of Mitomycin C varies based on the type of cancer being treated, the patient’s overall health, and other concurrent therapies. It is crucial to follow the oncologist’s recommendations.
- Monitoring: Patients receiving Mitomycin C should be closely monitored for signs of myelosuppression, renal function, and potential allergic reactions.
- Contraindications: Use with caution in patients with a history of hypersensitivity to Mitomycin C or those with severe renal impairment.
Mitomycin C remains a vital component in the arsenal against certain cancers, providing a targeted approach to treatment while necessitating careful management of potential side effects.